Shopping around carefully for plans will be important for Medicare Part D enrollees.
For Medicare Part D enrollees in 2016, it will pay to shop around during the open enrollment period because plan costs differ considerably with respect to what drugs are listed on formularies, their use of formulary tiers, and the level and structure of cost sharing applied to those tiers, according to an analysis by the Kaiser Family Foundation.
The difference is especially acute for those taking specialty prescription medications for conditions such as hepatitis C, multiple sclerosis, rheumatoid arthritis, and cancer, the report found. The differences can cost thousands of dollars for a single specialty drug even though Part D plans provide substantial protection against catastrophic costs. Medicare defines specialty drugs as those that cost more than $600 per month.
“The findings illustrate how high prescription drug prices, one of the public’s top health care concerns, pose a financial challenge not only for Medicare and other federal health programs but for people on Medicare as well,” the Kaiser Family Foundation noted.
The report found that for 12 specialty drugs used to treat these conditions, Part D beneficiaries face at least $4000 and as much as nearly $12,000 in out-of-pocket costs in 2016 for one drug alone. In 2014, 2% of Part D enrollees used these and other specialty tier drugs. The analysis also found that significant share of the out-of-pocket expenses for such drugs can be incurred even after enrollees’ drug spending reaches the drug benefit’s catastrophic threshold.
Out-of-pocket costs are substantially higher (often 10 times higher or more) for specialty drugs when they are not listed on formulary by a Part D plan. Six of the 12 specialty drugs included in the analysis were not on formulary in some plans, which triggered added costs of $40,000 or more annually, the report noted.
“With median income among Medicare beneficiaries at about $24,000 per person, the cost of off-formulary specialty and other high-priced drugs is beyond the reach of many Part D enrollees,” the authors wrote.
The report also shows how monthly out-of-pocket costs for commonly used brand and generic drugs can vary widely across plans, even when included on plan formularies: for five of the 10 top brands, monthly costs vary by as much as $100 across plans.
“Yet while it pays to shop, most people do not switch plans during the open enrollment period,” the authors concluded. “As a result, many Part D enrollees leave money on the table—sometimes thousands of dollars.”
Trump Administration’s Message to Supreme Court Puts New Wrinkle in Braidwood Case
February 21st 2025The Trump administration argues that HHS Secretary Robert F. Kennedy Jr can overrule the US Preventive Services Task Force to determine the preventive services covered under the Affordable Care Act.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
5 Key Health Care Moments During President Trump's First Month Back in Office
February 21st 2025President Donald J. Trump pushed for significant health care changes during his first month back in office, through executive orders affecting managed care, drug pricing, and clinical trial diversity guidance.
Read More
Same-Day Breast Imaging Gaps Reveal Health Care Disparities
February 18th 2025For this retrospective study, the authors examined data on more than 3 million screening mammographies for more than 1 million female patients; of the screenings, 23.6% had abnormal results and only 6.7% were recommended for biopsy.
Read More